Biofrontera Inc. BFRI 深 滬
已收盤 09-26 16:00:00 美东时间
0.9599
0.000
-0.02%
華盛通- 最 高0.97
- 今 開0.96
- 成交量 2.04万股
- 最 低 0.9303
- 昨 收 0.9601
- 總市值 1024.06万
- 52周最高 2.22
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.536
- 委 比 45.45%
- 總股本 1066.84万
- 歷史最高 292.60
- 量 比 0.11
- 振 幅 4.13%
- 歷史最低 0.536
- 每 手 1
- 風險率 0.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Biofrontera Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with a webcast presentation at 1:15 p.m. ET. The presentation will discuss the Company's dermatological products, including Ameluz® and RhodoLED® for photodynamic therapy. Management will also host one-on-one meetings with investors. For details, visit the conference website or contact Lytham Partners.
09-26 13:15
Biofrontera AG Announces Significant Impairment Losses
Biofrontera ( ($DE:B8FK) ) has shared an announcement. Biofrontera AG has annou...
09-25 05:27
Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
Biofrontera Inc. has appointed Lytham Partners to lead its investor relations program, aiming to expand its investor base and enhance market recognition. With significant progress, including restructuring, IP acquisition, manufacturing control, and $11 million funding, Biofrontera is positioned for profitability. Lytham Partners, renowned for its investor network and communication platforms, will assist in promoting Biofrontera's growth and value...
09-23 13:20
Biofrontera Completes Treatment Phase In Phase 3 Trial Of Ameluz For Actinic Keratosis On Body; Supplemental New Drug Application Planned For Submission In Q2 2026
All 172 patients have now entered the 12-month follow-up phaseTrial involves larger surface areas, building on the approval in October 2024 for use of up to 3 tubes of Ameluz® per treatmentStudy results expected to
09-16 22:32
Biofrontera shares are trading higher after the company announced that the final patient in its Phase 2b clinical trial evaluating Ameluz for the treatment of moderate to severe acne vulgaris completed participation. The company expects to receive top-line data in Q1 2026 and will present findings to the FDA in Q3 2026 as the basis for a future Phase III program.
Biofrontera shares are trading higher after the company announced that the fina...
08-25 20:29
Biofrontera Q2 EPS $(0.57) Misses $(0.42) Estimate, Sales $9.03M Beat $8.30M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.42) by 35.71 percent. This is a 1040 percent decrease over losses of $(0.05) per share from the
08-14 05:21
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
A Look at Biofrontera's Upcoming Earnings Report
Biofrontera (NASDAQ:BFRI) is set to give its latest quarterly earnings report o...
08-13 01:02
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
Biofrontera Inc. 宣布聘请George Jones为首席商务官，负责掌管公司的商业部门，包括销售、营销和市场准入。此次人事任命紧随公司与Biofrontera AG达成协议收购Ameluz®和RhodoLED®在美国市场的权益，这将显著提升公司的财务状况。Jones拥有超过25年的生物制药行业经验，其丰富的领导和团队建设经验将助力公司在光动力治疗领域进一步扩展。
08-11 20:25
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in dermatological products, will report its second-quarter and first-half 2025 financial results on August 13, 2025. A conference call to discuss the results will be held on August 14 at 10:00am ET. The call can be accessed via phone or webcast.
08-04 18:00
